The most powerful A1c-lowering medications available today are GLP-1 receptor agonists and dual-action drugs that combine GLP-1 with another gut hormone. Tirzepatide (Mounjaro) currently tops the list, reducing A1c by roughly 2.2 percentage points when added to metformin at its highest dose. Semaglutide (Ozempic) follows closely, with reductions of 1.9 to 2.2 points depending on the dose. But the “best” medication for you depends on more than raw A1c numbers. Your kidney health, heart disease risk, weight goals, and insurance coverage all shape which drug makes the most sense.
How Major Medication Classes Compare
Every diabetes medication lowers A1c to some degree, but the range is wide. Here’s what to expect from each class when used on its own:
- Metformin: about 1.0 to 1.5 percentage points
- GLP-1 receptor agonists: about 1.0 to 2.2 points, varying by specific drug and dose
- SGLT2 inhibitors (Jardiance, Farxiga): about 0.4 to 0.7 points
- DPP-4 inhibitors (Januvia, Tradjenta): about 0.5 to 0.7 points
These numbers shift depending on where your A1c starts. Someone beginning at 9.5% will generally see a bigger drop than someone starting at 7.5%, even on the same medication. The baseline matters a lot when interpreting clinical trial results.
Tirzepatide: The Strongest A1c Reducer
Tirzepatide works on two gut hormones simultaneously, which gives it an edge over older drugs that target only one. In FDA-reviewed clinical trials, the highest dose lowered A1c by 1.6 to 1.7 points more than placebo when used alone, and by 1.5 points more than placebo when added to insulin. Perhaps more telling, it outperformed semaglutide 1 mg head-to-head: the 15 mg dose dropped A1c an additional 0.5 points beyond what semaglutide achieved.
When added to metformin specifically, a large network analysis ranked tirzepatide 15 mg first among all GLP-1 class drugs, with an average A1c reduction of 2.23 percentage points compared to placebo. It also produced significant weight loss, averaging over 11 kg (about 25 pounds) in those same trials. That weight loss isn’t just cosmetic. Losing body fat directly improves how your cells respond to insulin, which helps sustain lower blood sugar over time.
Semaglutide: A Close Second With Strong Data
Semaglutide at its 2.0 mg dose lowered A1c by 2.2 percentage points from baseline in the SUSTAIN FORTE trial, while the 1.0 mg dose achieved a 1.9-point reduction. Both are substantial. When added to metformin, semaglutide 1.0 mg ranked second overall among GLP-1 drugs, with an average reduction of 1.57 points versus placebo.
Semaglutide comes in both injectable (Ozempic) and oral (Rybelsus) forms. The oral version at its highest dose reduced A1c by about 1.1 points when added to metformin, which is less potent than the injection but still meaningful for people who prefer a pill. The convenience trade-off is real: some people will take a daily pill consistently but skip weekly injections, and the medication you actually take always beats the one you don’t.
Why Metformin Is Still the Starting Point
Metformin has been the default first-line treatment for type 2 diabetes for decades, and that hasn’t changed in the 2025 guidelines. It lowers A1c by about 1.0 to 1.5 percentage points at full doses, primarily by reducing the amount of glucose your liver releases into your bloodstream. It’s inexpensive, available as a generic, well-studied over many years, and doesn’t cause weight gain.
When metformin alone isn’t enough, adding a second medication on top of it produces a combined effect. For example, adding semaglutide 1.0 mg to metformin drops A1c by an additional 1.57 points beyond metformin alone. This stacking approach is how many people reach their target. The 2025 American Diabetes Association guidelines actually push for earlier use of combination therapy rather than waiting months to see if metformin works by itself before adding something else.
SGLT2 Inhibitors: Modest A1c Impact, Major Organ Protection
SGLT2 inhibitors like empagliflozin (Jardiance) and dapagliflozin (Farxiga) work by causing your kidneys to excrete excess glucose into your urine. Their A1c reduction is modest, typically 0.4 to 0.7 percentage points, which makes them less impressive on paper than GLP-1 drugs. But these medications earn their place through benefits that go well beyond blood sugar.
For people with heart failure, SGLT2 inhibitors are considered first-line therapy. In clinical trials, dapagliflozin cut the combined risk of heart failure hospitalization or cardiovascular death by 47% in patients whose kidney function had declined significantly. For kidney protection, the data is equally striking: SGLT2 inhibitors reduced the risk of needing dialysis by 40 to 46% across multiple studies, even in people with advanced kidney disease. These drugs slow the annual rate of kidney function decline in a measurable, consistent way.
If you have both diabetes and kidney disease or heart failure, your doctor may prioritize an SGLT2 inhibitor regardless of its smaller A1c effect. The 2025 ADA guidelines recommend SGLT2 inhibitors for kidney and heart protection independent of whether your blood sugar is well controlled.
DPP-4 Inhibitors: A Milder Option
DPP-4 inhibitors lower A1c by 0.5 to 0.7 points, making them the least potent of the main medication classes. They work by boosting your body’s own gut hormones that trigger insulin release after meals. Their main advantage is tolerability: they cause fewer gastrointestinal side effects than GLP-1 drugs and are taken as a simple daily pill. For someone who can’t tolerate other options or whose A1c is only slightly above target, they can be enough. But for most people needing significant A1c reduction, they aren’t the strongest tool available.
Side Effects to Expect
GLP-1 drugs and tirzepatide commonly cause nausea, especially during the first few weeks or when the dose increases. Vomiting and diarrhea also occur. Most people find these effects fade as their body adjusts, which is why doctors start at a low dose and increase gradually over several months. SGLT2 inhibitors carry a different set of concerns: a higher rate of urinary tract infections and genital yeast infections, since they work by pushing glucose into the urine. In rare cases, they can trigger a dangerous condition called ketoacidosis.
Both GLP-1 drugs and SGLT2 inhibitors have specific situations where they shouldn’t be used. GLP-1 receptor agonists are contraindicated if you or a close family member has a history of medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2. For semaglutide specifically, an eye exam for diabetic retinopathy should happen before starting. SGLT2 inhibitors should be avoided in pregnancy and in situations where ketoacidosis risk is elevated.
How Long Before You See Results
A1c reflects your average blood sugar over the previous two to three months, so a single test won’t capture the full effect of a new medication right away. Most doctors recheck your A1c about three months after starting or changing a drug. That gives the medication time to reach its full dose (especially GLP-1 drugs, which are titrated up slowly) and allows enough red blood cell turnover for the A1c number to accurately reflect your new baseline. If your A1c hasn’t improved enough at that point, your doctor may increase the dose or add a second medication.
Picking the Right Medication for Your Situation
If pure A1c reduction is the goal and you have no other major health conditions, tirzepatide or semaglutide at higher doses will deliver the largest drops, often bringing people from well above target down to near-normal levels. If you have heart failure, an SGLT2 inhibitor should be part of your regimen for its protective effects, with a GLP-1 drug added for additional A1c and weight control. If kidney disease is your primary concern, SGLT2 inhibitors again take priority for slowing disease progression.
Cost and access remain practical barriers. Tirzepatide and semaglutide are expensive brand-name medications, and insurance coverage varies widely. Metformin costs pennies by comparison. For many people, the realistic “best” medication is the most effective one they can actually afford and take consistently. A combination of affordable metformin plus the most potent second agent your insurance covers will often outperform a single drug used alone.